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In this issue of Immunity, Ahern et al. (2010) show that IL-23R signaling in CD4+ T cells induces effector and
suppresses regulatory CD4+ T cells, which is critical for the development of intestinal, but not systemic,
inflammation.Different lineages of effector CD4+ T cells,
which include T helper 1 (Th1), Th2, and
Th17 cells, are important for the protec-
tion against different classes of patho-
gens. However, these effector CD4+
T cells may also respond to auto- or envi-
ronmental antigens, resulting in chronic
inflammatory or autoimmune diseases.
Therefore, the immune system has devel-
oped several mechanisms to control
these effector T cells. The two most stud-
ied subsets of CD4+ regulatory T cells,
which can control effector T cells,
are the Foxp3+CD4+CD25+ regulatory T
(Treg) cells and the T regulatory type 1
(Tr1) cells. The balance between effector
and Treg cells is crucial for the mainte-
nance of immune homeostasis, especially
in the intestine, where the immune sys-
tem is continuously confronted with com-
mensal microflora (Littman and Ruden-
sky, 2010). In contrast, imbalance
between effector and Treg cells is linked
to many human autoimmune and chronic
inflammatory diseases, one of which is
inflammatory bowel disease (IBD). The
cytokine IL-23 was shown to be important
for the sustenance of Th17 cell response
(McGeachy et al., 2009). IL-23 also plays
an important role in the development of
IBD in humans and in mouse colitis
models (Duerr et al., 2006; Elson et al.,
2007). However, precisely how IL-23
controls the development of intestinal
pathology and which cell type it acts on
is unclear. In this issue of Immunity, Ahern
et al. (2010) show that IL-23R signaling
in CD4+ T cells induces effector and
suppresses regulatory CD4+ T cells.
IL-23R signaling in T cells was therefore
critical for the development of intestinal
pathology.
The T cell transfer colitis model is
frequently used to study the balance150 Immunity 33, August 27, 2010 ª2010 Elsbetween effector and Treg cells in
the intestine. In this animal model,
CD4+CD25CD45RBhi cells (mainly naive
T cells) are transferred into an immune-
deficient host (Rag1/). Upon transfer
of the T cells to this lymphopenic environ-
ment, they proliferate, differentiate into
effector T cells, and cause pathology,
especially in the colon (Read et al.,
2000). T cell transfer colitis seems to be
mediated by both Th1 and Th17 cells
(Leppkes et al., 2009; Neurath et al.,
2002). In contrast, Treg and Tr1 cells, as
well as their cytokine products IL-10 and
TGF-b1, have been shown to have
protective functions in this model (Groux
et al., 1997; Li and Flavell, 2008; Read
et al., 2000).
In this issue of Immunity, Ahern et al.
(2010) aimed to study directly the role of
IL-23R signaling in T cells in colitis. To
that end, they transferred CD4+CD45RBhi
T cells isolated from wild-type or Il23r/
mice into Rag1/ hosts. Interestingly,
IL-23R signaling in T cells was critical for
the development of intestinal pathology,
but not of systemic inflammation. In line
with this observation, the authors found
that recipients of Il23r/ T cell had
reduced T cell numbers in the colon,
but not in the spleen. This effect was
not because of an altered migration of
Il23r/ T cell in the Rag1/ host, but
rather, was because of an impaired prolif-
eration of effector T cells in the colon.
These data indicate a tissue specific role
of IL-23R signaling.
CD4+ effector T cell lineages are
defined by the production of signature
cytokines and also, in some cases, by
the expression of a specific transcription
factor. Based on intracellular cytokine
staining for IL-17A and IFN-g, there are
three major effector T cell populationsevier Inc.that can be identified in the colon in the
T cell transfer colitis model. Those are
the IL-17A+IFN-g, IL-17A+IFN-g+, and
IL-17AIFN-g+ cells. However, it is not
clear whether the IL-17A and IFN-g
double producing cells are ‘‘Th17’’ or
‘‘Th1’’ cells. Therefore, these cells are
referred as ‘‘Th17+Th1’’ cells. Addition-
ally, there is increasing evidence that
Th17 cells are plastic and can differentiate
into other T cell lineages (e.g., Th1 cells).
In order to better understand the stability
and function of these ‘‘Th17’’ and ‘‘Th17+
Th1’’ cell subsets, further studies using
reporter mice to specifically isolate and
analyze these cells ex vivo will be essen-
tial. Nevertheless, it is interesting to eluci-
date which of these effector CD4+ T cell
subsets is dependent on IL-23R signaling
in colitis. Ahern et al. (2010) have found
that Rag1/ recipients of Il23r/
CD4+CD45RBhi T cells showed selec-
tive reduction in the frequency of IL-17A+
IFN-g+ cells, but not in IL-17A+IFN-g
or IL-17AIFN-g+ cells in the colon. In
addition, the frequency of Foxp3+ Treg
cells in the colon was also increased
compared to Rag1/ mice that received
wild-type CD4+CD45RBhi T cells. Thus,
IL-23 seems to inhibit Foxp3+ Treg
cells, while promoting the emergence of
IL-17A+IFN-g+ effector T cells, which are
together crucial for the development of
intestinal disease.
Because recipients of Il23r/ T cell
had strongly reduced total CD4+ T cell
numbers in the colon (including IL-17A+
IFN-g, IL-17A+IFN-g+, IL-17AIFN-g+
producing T cells), Ahern et al. employed
an elegant cotransfer systems aimed to
determine which of the T cell subsets
was reduced because of a direct cell
intrinsic effect of IL-23 on T cells and
whether there was a T cell extrinsic effect
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Figure 1. Direct and Indirect Effects of IL-23 on T Cell Subsets in the Colon
IL-23R signaling in CD4+ T cells is crucial for the accumulation of effector CD4+ T cells in the intestine.
It directly promotes IL-17A+IFN-g+ CD4+ T cells, while it inhibits Foxp3+ Treg cells. In contrast, IL-23 has
an indirect inhibitory effect on IL-10 producing cells (which might be Tr1 cells) via an unidentified
mediator. Additionally, IL-23 is indirectly promoting Th17 and Th1 cells, which might be mediated
by suppression of IL-10 production by CD4+ T cells. Therefore, IL-23 shifts the balance from an anti-
inflammatory to a proinflammatory milieu in the intestine via direct and indirect effects on CD4+ T cell
subsets.
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tory milieu in the mice receiving Il23r/
T cells. To this aim, they cotransferred
naive T cells isolated from CD45.2
wild-type or CD45.2+ Il23r/ mice into
Rag1/ recipients. Interestingly, the
presence of IL-23R-sufficient T cells and
their subsequent downstream inflamma-
tory signals were able to overcome the
requirement of IL-23R signaling for the
T cells to accumulate in the intestine.
These data contrast with a previous study
reporting a cell intrinsic role of IL-23R
expression in Th17 cell accumulation in
the brain during EAE (experimental auto-
immune encephalomyelitis), which could
not be overcome by the presence of
wild-type T cells (McGeachy et al., 2009).
Together, these data again indicate a
tissue-specific role of IL-23R signaling,
which requires further investigation of
the inflammatory milieu responsible for
this difference. Although the total num-
ber of CD45.2 wild-type and CD45.2+
Il23r/ T cells in the Rag1/ recipient
mice was only slightly different, Ahern
et al. (2010) still found a reduced fre-
quency of CD45.2+IL-17A+IFN-g+ T cells
and an increased frequency ofCD45.2+Foxp3+ T cells compared to
the CD45.2 wild-type population in the
colon. These data indicated that these
two important effector and regulatory
T cell subsets are directly controlled by
cell intrinsic IL-23R signaling in T cells
(Figure 1). Despite the difference in these
subsets, the incidence and severity of
colitis were similar between Rag1/
mice receiving mixture of CD45.2 wild-
type and CD45.2+ Il23r/ T cells or
wild-type naive T cells only. This suggests
that IL-23 either induces a potent pro-
inflammatory response or inhibits an
important anti-inflammatory factor in the
IL-23 responsive wild-type T cells, which
then acts on the cotransferred Il23r/
T cells.
Ahern et al. found that IL-10 production
by Il23r/ T cells was increased com-
pared to wild-type T cells, when these
cells were transferred alone into Rag1/
recipients. By contrast, Il23r/ T cells
isolated from the colon of mice cotrans-
ferred with wild-type cells did not demon-
strate increased IL-10 production. These
data suggest that IL-23 responsive
T cells somehow suppress the increased
IL-10 production by Il23r/ T cellsImmunity 33(Figure 1). This is a very interesting finding,
although it warrants further exploration:
Several T cell subsets including Treg,
Tr1, and also Th17 cells are able to
produce IL-10 (Li and Flavell, 2008). Addi-
tionally, a variety of immune cells can
respond to IL-10. It is not clear whether
IL-10 acts on antigen-presenting cells or
directly on different T cell subsets, which
include IL-17A+IFN-g, IL-17A+IFN-g+,
IL-17AIFN-g+, and also Treg cells,
in the inflamed colon. Further studies
using mouse models with cell-specific
blockade of IL-10 signaling in combina-
tion with reporter mice seem to be essen-
tial to address this important question.
The balance between effector and
regulatory CD4 T cell is of great impor-
tance for the maintenance of immune
homeostasis, especially in the colon.
Ahern et al. demonstrated that IL-23R
signaling in T cells themselves has an
important impact on this balance in the
colon. They found that IL-23R signaling
in T cells played a crucial role for their
proliferation and accumulation in the
colon. This was mediated via an indirect
cell extrinsic effect on IL-17A+IFN-g,
IL-17A-IFN-g+ and IL-10-producing
T cells. But more importantly, IL-23R
signaling promoted the emergence of
IL-17A+IFN-g+ T cells, while inhibiting
Foxp3+ Treg in a direct manner (Figure 1).
Thus IL-23 has a dual effect acting on
regulatory and effector T cells. Consid-
ering the human genetic studies, which
link IL-23R signaling to the pathogenesis
of IBD, the data by Ahern et al. implicate
that blockade of IL-23 might restore the
balance between effector and regulatory
T cells in IBD.REFERENCES
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